Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Introduction: A substantial number of therapeutic drugs for Alzheimer's disease (AD) have failed in late-stage trials, highlighting the translational disconnect with pathology-based animal models. Methods: To bridge the gap between preclinical animal models and clinical outcomes, we implemented a conductance-based computational model of cortical circuitry to simulate working memory as a measure for cognitive function. The model was initially calibrated using preclinical data on receptor pharmacology of catecholamine and cholinergic neurotransmitters. The pathology of AD was subsequently implemented as synaptic and neuronal loss and a decrease in cholinergic tone. The model was further calibrated with clinical Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) results on acetylcholinesterase inhibitors and 5-HT6 antagonists to improve the model's prediction of clinical outcomes. Results: As an independent validation, we reproduced clinical data for apolipoprotein E (APOE) genotypes showing that the ApoE4 genotype reduces the network performance much more in mild cognitive impairment conditions than at later stages of AD pathology. We then demonstrated the differential effect of memantine, an N-Methyl-D-aspartic acid (NMDA) subunit selective weak inhibitor, in early and late AD pathology, and show that inhibition of the NMDA receptor NR2C/NR2D subunits located on inhibitory interneurons compensates for the greater excitatory decline observed with pathology. Conclusions: This quantitative systems pharmacology approach is shown to be complementary to traditional animal models, with the potential to assess potential off-target effects, the consequences of pharmacologically active human metabolites, the effect of comedications, and the impact of a small number of well described genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · cited 1×
“Such a value is in line with the compensatory differences in ChAT staining observed in the brain of MCI patients [69].”
ResultBall, M. J. (1977) · Acta Neuropathologica · doi:10.1007/bf00692056 · Cited by 639 · cited 1×
“We implement AD pathology as a loss of cortical neurons [39] at a rate, τ N (%/week) and synapses from pyramidal neurons [40] with a rate τ S (%/week).”
MethodMultiple models to capture the variability in biological neurons and networks
Marder, E., & Taylor, A. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2735 · Cited by 451 · cited 1×
“This is not unlike the observation that many different parameter sets might lead to identical emergent properties [89].”
BackgroundStructural Correlates of Cognition in Dementia: Quantification and Assessment of Synapse Change
DeKosky, S. T., Scheff, S. W., & Styren, S. D. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0056 · Cited by 405
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Cellular mechanisms of neuronal population oscillations in the hippocampus in vitro
Traub, R. D., Bibbig, A., LeBeau, F. E. N., Buhl, E. H., & Whittington, M. A. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.27.070203.144303 · Cited by 358 · cited 1×
“To model the response of excitatory synaptic inputs, we implemented an excitatory chemical synaptic input as in published models of AMPA and NMDA synapses [29].”
Method
Cited by
Building a knowledge graph to enable precision medicine
Chandak, P., Huang, K., & Zitnik, M. (2023) · Scientific Data · doi:10.1038/s41597-023-01960-3 · Cited by 522
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Lang, F. M., Mo, Y., Sabbagh, M., Solomon, P., Boada, M., Jones, R. W., Frisoni, G. B., Grimmer, T., Dubois, B., Harnett, M., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12136 · Cited by 34
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21
“29 In that way, the system’s readout can be demonstrated to be strongly correlated to a clinical scale of interest, such as Alzheimer’s Disease Assessment Scale – Cognitive (ADAS-Cog) 28 or the Unified Parkinson’s Disease Rating Scale.”
BackgroundMethodSelf-citationGeerts, H., Hofmann‐Apitius, M., Anastasio, T. J., & Initiative, B. H. M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.011 · Cited by 20
Self-citation
Metadata
- Authors
- Roberts, P. D., Spiros, A., & Geerts, H.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2012-11-26
- Volume
- 4
- Issue
- 6
- Pages
- 50-50
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2157711998
- Cited by
- 47
- References
- 13
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.